Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (364)	11/18/1999 10:29:00 AM
From: Bob L	Respond to of 666

They are using dosimetry in the Zevalin trial to work out a standardized dosing method, so they won't have to use dosimetry in treatment eventually.

To: Vector1 who wrote (364)	11/18/1999 10:36:00 AM
From: biowa	Respond to of 666

V1 <<Can someone help explaining why the abstract says that there was dosemitry used. I thought Zev didn't use dosemitry.>> They have another abstract showing that Zevalin biodistribution and organ dosing isn't affected by prior treatment w/ Rituxan. They appear to be doing dosimetry in the clinical studies to demonstrate that its unnecessary in clinical application; that a standard dose (0.4mCi/kg) is appropriate. At least that's what it looks like to me. biowa